Ki-67 Proliferation Index: Correlation with Prognostic Parameters and Outcome in Multiple Myeloma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 1, 2004, Pages 8-13

  Alexandrakis, Michael G ^a   Passam, Freda H ^a   Kyriakou, Despina S ^b   Dambaki, Konstantina ^a   Niniraki, Maria ^a   Stathopoulos, Efstathios ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b University Hospital of Thessalia   (Greece)

Author keywords

IL 10; IL 6; Ki 67; Multiple myeloma

Indexed keywords

BETA 2 MICROGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 6; KI 67 ANTIGEN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER PATIENT; CANCER STAGING; CELL DIVISION; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PARAMETER; PLASMA CELL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; BONE MARROW; BONE MARROW EXAMINATION; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; KI-67 ANTIGEN; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL RATE;

EID: 0842327296     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000045810.91816.41     Document Type: Article

References (26)

1. Anderson KC. Multiple myeloma. Advances in disease biology: therapeutic implications. Semin Hematol 2001;38:6-10.
2. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 1999;13:1295-314.
3. Greipp P, Lust J, O'Fallon M, et al. Plasma cell labeling index and b2-microglobulin predict survival independent of thymidine kinase and c-reactive protein in multiple myeloma. Blood 1993;12:3382-7.
4. Girino M, Riccardi A, Luoni R. Monoclonal antibody Ki67 as a marker of proliferative activity in monoclonal gammopathies. Acta Haematol 1991;85:26-30.
5. Kanavaros P, Stefanaki K, Vlachonikolis J, et al. Immunohistochemical expression of the p53, p21/waf-1, RL and Ki67 proteins in multiple myeloma. Anticancer Res 2000;20:4619-25.
6. Klein B, Zhao-Yang L, Zong Jlang G, et al. Interleukin-10 and Gp130 cytokines in human multiple myeloma. Leuk Lymphoma 1999;34:63-70.
7. Frassanito MA, Cusmai A, Iodice G, et al. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001;97:483-9.
8. Turesson I, Abildgaard N, Ahlgren T, et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 1999;106:1005-12.
9. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842-54.
10. Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective southwest oncology Group trial. Blood 1994;83:1460-6.
11. Goodson WH, Moore DH, Ljung BM, et al. The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treat 2000;59:113-23.
12. Durie BGM, Salmon SE, Moon TE. Pretreatment tumor mass, cell kinetics and prognosis in multiple myeloma. Blood 1980;55:364-72.
13. Lai R, Medeiros L, Wilson C. Expression of the cell-cycle-related proteins E2F-1, p53, mdmp21 waf-1, and Ki67 in multiple myeloma: correlation with cyclin D1 immunoreactivity. Mod Pathol 1998;11:642-7.
14. Drach J, Gattringer C, Glassl H. The biological and clinical significance of the Ki67 growth factor in multiple myeloma. Hematol Oncol 1992;10:125-34.
15. Pellegrini W, Facchetti F, Marocolo D, et al. Assessment of cell proliferation in normal and pathological bone marrow biopsies: a study using double sequential immunophenotyping on paraffin sections. Histopathology 1995;27:397-405.
16. Lokhurst H, Boom S, Terpstra W. Determination of the growth fraction in monoclonal gammopathies with the monoclonal antibody Ki67. Br J Haematol 1988;69:477-81.
17. Falini B, Canino S, Sacchi S. Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki67 and anti-bromo-deoxyuridine monoclonal antibodies. Br J Haematol 1988;69:311-20.
18. Dalton WS, Jove R. Drug resistance in multiple myeloma: approaches to circumvention. Semin Oncol 1999;26:23-7.
19. Barille S, Bataille R, Amiot M. The role of interleukin-6 and interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw 2000;11:546-51.
20. Anderson KC, Jones RM, Morimoto C, et al. Response pattern of purified myeloma cells to hematopoietic growth factors. Blood 1989;73:1915-24.
21. Thaler J, Fechner F, Herold M. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki67 proliferation index. Leuk Lymphoma 1994;12:265-71.
22. Lu Z, Zhang X, Rodriguez C. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995;85:2521-7.
23. Simonsson B, Kallander CF, Brenning G, et al. Biochemical markers in multiple myeloma: a multivariate analysis. Br J Haematol 1988;69:47-53.
24. Bataille R, Boccadoro M, Klein B, et al. C reactive protein and b2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733-7.
25. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 1991;115:931-5.
26. Simonsson B, Brenning G, Kallander C, et al. Prognostic value of serum lactate dehydrogenase (S-LDH) in multiple myeloma. Eur J Clin Invest 1987;17:336-9.